UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2015
Commission File Number: 001-36515
Materialise NV
Technologielaan 15
3001 Leuven
Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MATERIALISE NV | ||
| By: | /s/ Wilfried Vancraen | |
| Name: | Wilfried Vancraen | |
| Title: | Chief Executive Officer | |
Date: June 9, 2015
EXHIBIT INDEX
| Exhibit |
Description | |
| 99.1 | Press Release | |
Exhibit 99.1
Materialise NV Announces Changes to Board of Directors
Leuven, Belgium – June 9, 2015. Materialise NV (Nasdaq: MTLS), a leading provider of 3D printing software and sophisticated 3D printing solutions in the medical and industrial markets, today announced, further to its ordinary General Assembly, that Ms. Lieve Verplancke has joined its board of directors and that Mr. Guy Weyns and Mr. Bart Luyten (representing Sniper Investments NV) have stepped down.
Executive Chairman Peter Leys commented, “On behalf of the entire Board, I would like to welcome Lieve Verplancke, who brings three decades of commercial experience in the healthcare sector to Materialise. We are delighted to have the opportunity to benefit from her vast knowledge and the many diverse roles she has played in the industry.”
Ms. Verplancke began her career with Beecham Group/GlaxoSmithKline in 1984 and later held key management positions with leading pharmaceutical companies Merck & Co. and Bristol-Myers Squibb. At Bristol Myers Squibb, she served as Managing Director, leading their Belgian/GDL subsidiary for 18 years. She currently serves on the board of a large hospital group in Belgium and of a Euronext-listed investment fund.
Ms. Verplancke is a medical doctor (MD) and holds a postgraduate degree in economics as well as an MBA. In addition, she is a certified Executive Coach (PCC) with expertise in helping organizations increase their effectiveness and build relationships. Ms. Verplancke will serve on the board’s Audit Committee.
Mr. Leys continued, “I would also like to thank Guy and Bart for their many contributions to Materialise. We benefited greatly from their financial insights and capital markets expertise, particularly during our IPO process.”
About Materialise
With its headquarters in Leuven, Belgium, and branches worldwide, Materialise is a provider of Additive Manufacturing (AM) software solutions and sophisticated 3D printing services in a wide variety of industries, including healthcare, automotive, aerospace, art and design and consumer products. Materialise has been playing an active role in the field of AM since 1990, through its involvement in AM for industrial and medical applications, by providing biomedical and clinical solutions such as medical image processing and surgical simulations and by developing unique solutions for its customers’ prototyping, production, and medical needs. For additional information, please visit: www.materialise.com.
Press contacts:
Vanessa Palsenbarg
Corporate Communications Specialist, Materialise
Phone: +32 16 39 66 37
Fax: +32 16 39 66 00
Email: press@materialise.com
Twitter: @belgiancanuck or @MaterialiseNV
Visit: www.materialise.com
Investor Contacts:
Harriet Fried/Jody Burfening
LHA
Phone: +1-212-838-3777
Email: hfried@lhai.com